Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

INTRODUCTION: Gastrointestinal (GI) adverse events (AEs) are the most common AEs with glucagon-like peptide-1 receptor agonists (GLP-1RAs). Weight loss (WL) is slightly greater in people who experience GI AEs than those who do not. A previous mediation analysis of the SUSTAIN 1–5 trials indicated mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lingvay, Ildiko, Hansen, Thomas, Macura, Stanislava, Marre, Michel, Nauck, Michael A, de la Rosa, Raymond, Woo, Vincent, Yildirim, Emre, Wilding, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Emerging Technologies, Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594204/
https://www.ncbi.nlm.nih.gov/pubmed/33115821
http://dx.doi.org/10.1136/bmjdrc-2020-001706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594204/
https://www.ncbi.nlm.nih.gov/pubmed/33115821
http://dx.doi.org/10.1136/bmjdrc-2020-001706

Ejemplares similares